FIELD: medicine.
SUBSTANCE: group of inventions concerns a bispecific antibody containing a first antibody variable domain capable of recruiting human immune effector cell activity by specific binding to CD3, and a second antibody variable domain capable of specifically binding to the desired antigen. Group of inventions also relates to nucleic acid coding said antibody; a vector comprising a nucleic acid; a pharmaceutical composition for treating cancer associated with B-cells, containing a bispecific antibody; method of treating cancer associated with B-cells in a subject comprising administering to a subject in need thereof an effective amount of a bispecific antibody.
EFFECT: group of inventions provides treating cancer associated with B-cells.
18 cl, 22 ex, 16 dwg, 14 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| CHIMERIC ANTIGENIC RECEPTORS AIMED AT ANTIGEN OF AGING OF B-CELLS | 2016 |
|
RU2706582C2 |
| MOLECULES THAT BIND BCMA AND USE OF SUCH MOLECULES | 2019 |
|
RU2812322C2 |
| BISPECIFIC SINGLE-CHAIN ANTIBODY TO PSMAxCD3 WITH INTERSPECIES SPECIFICITY | 2011 |
|
RU2617942C2 |
| ANTIBODIES AGAINST 5-BROMO-2'-DEOXYURIDINE AND METHODS OF USE | 2015 |
|
RU2705299C2 |
| THERAPEUTIC DLL4-BINDING PROTEINS | 2010 |
|
RU2570639C2 |
| THEOPHYLLINE ANTIBODIES AND METHODS FOR THEIR APPLICATION | 2013 |
|
RU2630664C2 |
| PSCAXCD3, CD19XCD3, C-METXCD3, ENDOSIALIN XCD3, EPCAMXCD3, IGF-1RXCD3 OR FAP-ALPHA XCD3 BISPECIFIC SINGLE-CHAIN ANTIBODY WITH INTER-SPECIES SPECIFICITY | 2009 |
|
RU2547600C2 |
| BISPECIFIC ANTIBODY AND ITS USE | 2019 |
|
RU2785292C2 |
| IL-12/P40 BINDING PROTEINS | 2006 |
|
RU2461571C2 |
| ANTI-IDIOTYPIC ANTIBODIES AND METHODS RELATED TO THEM | 2017 |
|
RU2773355C2 |
